Indeed, siRNA silencing of STAT3 combined with oxaliplatin therapy, in mouse models of metastatic colorectal cancer (HCT116), was previously found to reduce tumor size better than either drug separately (Shahzad et al. 2011). Here, STAT3 is linked to metastatic colorectal cancer.